AACC 2023 Annual
& Clinical Lab Expo
We pioneer breakthroughs in healthcare. For everyone. Everywhere.
Every blood test tells a story.
And just as that blood is unique, so is your network, your lab, your processes, and your staff.
Click to jump to
Important AACC 2023 information
Continuous innovation for a lifetime of answers
AACC 2023 Annual Scientific Meeting & Clinical Lab Expo
Join Siemens Healthineers at AACC 2023
July 23-27, 2023
Anaheim Convention Center, Anaheim, California, USA
Integrated, intelligent, and fully customizable solutions to enhance diagnostic potential—for every patient and clinical environment
Read highlights from 2022 AACC in Chicago.
Join Siemens Healthineers at upcoming conferences and trade shows for laboratory diagnostics.
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events. The test is not for use in the diagnosis of NASH or for the staging of fibrosis.